May 19, 2016
Perspectives on Key Presentations in GI Cancer from ASCO-GI 2022: Part I
Rapid Reactions is a video series that provides commentary from key experts summarizing data released at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) focused on gastric, gastroesophageal, and esophageal cancer. Please join Minsig Choi, MD, from Stonybrook University Cancer Center, as he discusses the following 3 pivotal presentations from ASCO-GI 2022:
- Updated results of the CheckMate-649 study indicated that nivolumab plus chemotherapy continued to demonstrate clinically meaningful improvement in efficacy with longer follow-up, with no emergence of new safety issues
- Results of the multicohort phase 1/2 KRYSTAL-1 study indicated that adagrasib monotherapy was well tolerated and demonstrated encouraging clinical activity in pretreated patients with GI tumors harboring a KRAS G12C mutation
- Updated results of the DESTINY-Gastric01 trial indicated that T-DXd therapy continued to demonstrate overall survival benefit compared with chemotherapy, accompanied by a manageable safety profile, in previously treated patients with HER2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma
Read the Articles Discussed in the Video
-
Nivolumab plus Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: Expanded Analysis from CheckMate 649
-
KRYSTAL-1: Adagrasib in Previously Treated Patients with Unresectable or Metastatic Pancreatic Cancer and Other Gastrointestinal Tumors with a KRAS G12C Mutation
-
Improved Survival with Trastuzumab Deruxtecan in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DESTINY-Gastric01
Related Articles
Web Exclusives - November 5, 2018
Oral Toxicities Associated with Cancer Therapies: What’s Old Is New Again
According to Nathaniel S. Treister, DMD, DMSc, although it may appear that new cancer therapies are associated with novel oral toxicities, these toxicities closely mimic other well-known conditions, and, in reality, aren’t always so novel.
Uncategorized - August 7, 2015
Patient Access to Targeted Therapies Updated VOL 1, NO 1
Molecular diagnostics are at the center of personalized healthcare. In July 2012, a rapid molecular test for Kirsten RNA associated rat sarcoma 2 virus gene (KRAS) mutations—the therascreen KRAS RGQ PCR Kit (therascreen KRAS test)—was the first to receive approval from the US Food and Drug Administration (FDA) as a [ Read More ]
- Nivolumab plus Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: Expanded Analysis from CheckMate 649
- KRYSTAL-1: Adagrasib in Previously Treated Patients with Unresectable or Metastatic Pancreatic Cancer and Other Gastrointestinal Tumors with a KRAS G12C Mutation
- Improved Survival with Trastuzumab Deruxtecan in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DESTINY-Gastric01
Related Articles
Web Exclusives - November 5, 2018
Oral Toxicities Associated with Cancer Therapies: What’s Old Is New Again
According to Nathaniel S. Treister, DMD, DMSc, although it may appear that new cancer therapies are associated with novel oral toxicities, these toxicities closely mimic other well-known conditions, and, in reality, aren’t always so novel.
Uncategorized - August 7, 2015
Patient Access to Targeted Therapies Updated VOL 1, NO 1
Molecular diagnostics are at the center of personalized healthcare. In July 2012, a rapid molecular test for Kirsten RNA associated rat sarcoma 2 virus gene (KRAS) mutations—the therascreen KRAS RGQ PCR Kit (therascreen KRAS test)—was the first to receive approval from the US Food and Drug Administration (FDA) as a [ Read More ]